PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 22, 2026Cancer Research

Abstract PR024: Circulating tumor DNA methylation captures epigenetic changes in patients induced by the PRC2 inhibitor ORIC-944

View Full Paper
Ask AI
Bookmark
Share

Authors

AWAmber W. WangMPMichal PawlakEAEric Ariazi

Discussion

Loading...

Member takes

Overview

Clinical evaluation demonstrates ORIC-944's impact on epigenetic changes in prostate cancer, suggesting enhanced treatment efficacy.

Key Points

  • This research aims to explore the epigenetic mechanisms by which ORIC-944 influences prostate cancer treatment response.
  • Evaluated clinical samples from mCRPC patients in the ORIC-944-01 Phase 1b trial.
  • Utilized DNA methylation profiling from liquid biopsies for non-invasive epigenetic analysis.
  • Developed a custom panel based on CpG-rich regions from previous DNA methylation data.
  • Enhanced AR signaling observed in tumor methylation patterns after one treatment cycle of ORIC-944.
  • No increase in neuroendocrine-associated methylation signals in any patients post-treatment.
  • Findings align with preclinical data, supporting the potential of ORIC-944 in overcoming treatment resistance.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6971bfdff17b5dc6da021f50https://doi.org/10.1158/1538-7445.prostateca26-pr024
View Full Paper
Ask AI
Bookmark
Share